Baxter International Inc (BAX)
10 Mar 2014
|Market Cap (Mil.):||$36,665.17|
|Shares Outstanding (Mil.):||543.19|
BRIEF-Cell Therapeutics up 8.6 percent premarket; expects $67 million in cash milestone payments from Baxter through 2015
NEW YORK, Nov 18 - Cell Therapeutics Inc : * Up 8.6 percent to $2.03 in premarket; expects $67 million in cash milestone payments from Baxter through 2015
BRIEF-Cell Therapeutics expects to get $67 mln in cash milestone payments from Baxter through 2015 - SEC filing
Nov 18 - Cell Therapeutics Inc : * Expects could pay up to $96 million in development costs for persist-1 & 2
- Cell Therapeutics Inc's shares rose as much as 24 percent after Baxter International Inc threw its financial and marketing heft behind the smaller company's bone marrow disorder drug.
(Adds details, CEO comments from conference call, analyst comments; adds share movement)
Nov 15 - Baxter International Inc agreed to develop and market Cell Therapeutics Inc's bone marrow disorder drug for payments that could total up to $362 million, sending Cell Therapeutics' shares up more than 30 percent before the bell.
- The U.S. Food and Drug Administration said on Friday it has approved Baxter International Inc's nutritional supplement Clinolipid, moving quickly to alleviate a drug shortage.
Oct 4 - The U.S. Food and Drug Administration said on Friday it has approved Baxter International Inc's nutritional supplement Clinolipid, moving quickly to alleviate a drug shortage.
Earnings vs. Estimates
Analyst Research Reports
Provider: Wright Reports
Trading Report for (BAX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: S&P Capital IQ – STARS Reports
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.